Browsing Tag
FASENRA
4 posts
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive
AstraZeneca’s Fasenra failed to hit its COPD trial endpoint, but stock rose 0.44% as investors bet on pipeline strength and respiratory growth.
AstraZeneca’s Fasenra meets primary endpoint in MANDARA Phase 3 trial for EGPA
AstraZeneca’s Fasenra met its primary endpoint in the MANDARA Phase III trial, offering a monthly treatment option for…
FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP
The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of…